Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
| Revenue (TTM) | $2.71B |
| Gross Profit (TTM) | $1.77B |
| EBITDA | $-224.42M |
| Operating Margin | -10.30% |
| Return on Equity | -12.50% |
| Return on Assets | -8.08% |
| Revenue/Share (TTM) | $19.32 |
| Book Value | $12.68 |
| Price-to-Book | 30.93 |
| Price-to-Sales (TTM) | 21.77 |
| EV/Revenue | 20.49 |
| EV/EBITDA | -26.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 37.70% |
| Shares Outstanding | $144.14M |
| Float | $140.10M |
| % Insiders | 2.81% |
| % Institutions | 96.73% |
Volatility is currently expanding
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with rese.
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.
Quarterly 13F disclosures offer individual investors an irreplaceable window into the playbooks of market-moving institutions.
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA (ctDNA) dynamics as part of trea.
Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NTRA and any ticker you trade — then tracks every position and per-strategy win rate.
